Skip to main content

Advertisement

SpringerLink
Log in

Is there a role for ovarian function suppression in operable breast cancer?

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 27 February 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107

    Article  Google Scholar 

  2. Carlson RW, Allred DC, Anderson BO et al (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122–192

    CAS  PubMed  Google Scholar 

  3. Cuzick J, Ambroisine L, Davidson N et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723

    Article  CAS  PubMed  Google Scholar 

  4. Thurlimann B, Price KN, Gelber RD et al (2009) Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113:137–144

    Article  PubMed  Google Scholar 

  5. Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725

    Article  PubMed  Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group (EBCTG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Google Scholar 

  7. Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779

    Article  CAS  PubMed  Google Scholar 

  8. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  CAS  PubMed  Google Scholar 

  9. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167

    Article  PubMed  Google Scholar 

  10. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734

    Article  CAS  PubMed  Google Scholar 

  11. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65

    Article  CAS  PubMed  Google Scholar 

  12. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312

    Article  CAS  PubMed  Google Scholar 

  13. Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165

    Article  CAS  PubMed  Google Scholar 

  14. Carlson RW, Brown E, Burstein HJ et al (2006) NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4 Suppl 1:S1–S26

    PubMed  Google Scholar 

  15. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329

    Article  CAS  PubMed  Google Scholar 

  16. Lo SS, Mumby PB, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671–1676

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albert Einstein College of Medicine, Montefiore Medical Center, 1825 Eastchester Road, Bronx, NY, 10461, USA

    Joseph A. Sparano

Authors
  1. Joseph A. Sparano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph A. Sparano.

Additional information

This is an invited commentary to article doi: 10.1007/s10549-010-0794-2.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sparano, J.A. Is there a role for ovarian function suppression in operable breast cancer?. Breast Cancer Res Treat 123, 311–313 (2010). https://doi.org/10.1007/s10549-010-0874-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0874-3

Keywords

Search

Navigation